Novo Nordisk

Novo Nordisk Faces Revenue Decline Amid Price Cuts and Patent Challenges

Rising Gallbladder Surgeries and Pancreatitis Risks Linked to Weight-Loss Injections

Weight-Loss Injections Transform Consumer Habits Amidst Counterfeit Pill Concerns

FDA Approves First Oral Wegovy Pill for Obesity Treatment

Novo Nordisk's Semaglutide Fails to Slow Alzheimer's Progression, Shares Plummet

Trump Strikes Deals to Slash Weight-Loss Drug Prices and Expand Access

Eli Lilly Raises UK Price of Mounjaro Amid Global Pricing Pressure

Novo Nordisk Faces Challenges Amidst Rising Competition in Weight-Loss Drug Market